Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study

1. Dimopoulos, M.
2. Wang, M.
3. Maisnar, V.
4. Minarik, J.
5. Bensinger, W.
6. Mateos, M.-V.
7. Obreja, M.
8. Blaedel, J.
9. Moreau, P.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1186/S13045-018-0583-7 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

•